





World Hepatitis Alliance



ANNUAL REPORT




2025






FOREWORD FROM THE PRESIDENT



This year, as we reach the end of the World Hepatitis Alliance's 2021-2025 strategy, I am struck by both how far we have come and how much work remains ahead of us. With just five years left until the 2030 hepatitis elimination target, 2025 was a year that reminded us that progress is possible when communities, advocates, governments, and partners work together.

One of the most significant achievements of 2025 was the growth of our membership. We welcomed 86 new members from 25 new countries.

Throughout the year, we saw the power of community-led action driving change across the hepatitis response. From the launch of the new SAFEStart+ project focused on preventing vertical transmission, to our research on hepatitis delta and on hepatitis related stigma, people with lived experience continued to inform our progammes and influence decision-making at every level.

At the same time that we celebrate these achievements, the need for urgent action remains clear. More than 300 million people continue to live with viral hepatitis, millions remain undiagnosed, and too many people still face barriers to testing, treatment, and care.







What gives me hope is the strength of our global community. Every achievement highlighted in this report reflects the dedication of WHA members, partners, supporters, and advocates who are working to increase the urgency and speed of the global response. Together, you have raised awareness, influenced policy, strengthened health systems, and brought us closer to a world free from viral hepatitis.

As I conclude my term as President of the World Hepatitis Alliance and hand over the presidency to Dee Lee, I do so with great confidence and optimism for the future of our movement. While I recognise that there is still much work to be done, I am inspired by the commitment, expertise, and passion of our community, which has never been stronger. Together, we must build on this momentum, continue to hold decision-makers accountable, accelerate progress towards hepatitis elimination, and ensure that no one affected by hepatitis is left behind.

Rachel Halford, World Hepatitis Alliance President

ABOUT THE WORLD HEPATITIS ALLIANCE

The World Hepatitis Alliance (WHA) is a global network of more than 400 civil society and community organisations across over 125 countries, united by the goal of eliminating viral hepatitis by 2030. We are led and governed by people with lived experience of hepatitis, ensuring their voices and perspectives are at the centre of everything we do. Together, we drive the global response to hepatitis through advocacy, capacity building, and raising awareness.

Since our founding in 2007, WHA has led major global awareness campaigns, helped build a powerful international movement, strengthened civil society, and amplified the voices of people living with hepatitis. Our sustained advocacy at the highest levels contributed to a landmark moment in 2016, when 194 governments committed to eliminating viral hepatitis by 2030. Since then, we have continued to hold countries accountable by working alongside governments and communities to accelerate progress. We remain steadfast in our commitment and will not stop until hepatitis is eliminated everywhere.

Our members are at the forefront of the global hepatitis response. They provide essential services, support, and guidance to people living with hepatitis, while advocating for the needs of affected communities. Their work enables WHA to represent the collective voice of millions of people worldwide impacted by hepatitis.

VISION

A world free from viral hepatitis

MISSION

Harness the power of people living with viral hepatitis to achieve its elimination

CONTENTS

Foreword from the President ▸ 2

About the World Hepatitis Alliance ▸ 3

A message from WHA CEO Cary James ▸ 12

Snapshot 2025 ▸ 13

Our strategy ▸ 15

Four pillars for 2025 ▸ 16

World Hepatitis Day 2025 ▸ 18


Liver cancer and NCDs ▸ 22

Eliminating vertical transmission ▸ 24

World Hepatitis Testing Week 2025 ▸ 28

Community Impact Programme ▸ 32

NOhep Medical Visionaries ▸ 34



Hepatitis Delta Global Landscape Survey Report ▸ 38

The Hepatitis Stigma Survey ▸ 40

Communications ▸ 42

PHOTOS ▸ 44


New members 2025 ▸ 46

Governance and financial overview ▸ 50

Income and expenditure statement ▸ 52

Acknowledgements and partner recognition ▸ 55

VIRAL HEPATITIS: A GLOBAL CRISIS



Hepatitis is the world's deadliest communicable disease. Every year,

1.3 million

people lose their lives to hepatitis, and the number of deaths is rising.

Almost

300 million

people live with viral hepatitis

3.5%

of the global population is living with either hepatitis B or C

There are nearly

2 million

new cases of viral hepatitis every year

Hepatitis is the leading cause of liver cancer

HOW IS HEPATITIS TRANSMITTED?

Vertical transmission

Unsafe injections

Blood-to-blood contact and contaminated blood products

THE SOLUTION

Prevent, test and treat viral hepatitis

with a vaccine and effective treatments for hepatitis B and a cure for hepatitis C


With concerted action, political will and innovative financing, we can reach the elimination goals

In 2016, all 194 Member States of the World Health Organization (WHO) signed up to eliminate viral hepatitis by 2030, but progress remains too slow

Hep-voices

ANTONIO'S STORY

Antonio Oñate is the Director of Hepatos Aión Foundation AC, an non-governmental organisation (NGO) committed to raising awareness about liver health, and a regional board member for the Pan American Health Organisation at the World Hepatitis Alliance. A tireless advocate for hepatitis elimination across Latin and North America, Antonio is determined to strengthen regional collaboration and push for greater action.











What's something people are always surprised to learn about you?

How I managed my hepatitis C diagnosis, how I improved the damage caused by cirrhosis, and how I contracted the disease due to medical issues I faced during the first 15 years of my life.

How would your best friend describe you in 3 words?

My best friend says: A good man.

What's a normal day in your life like?

I usually wake up at 5:30am and start my day with breakfast. I check both my foundation and personal emails, and if there's a webinar scheduled, I participate. I take my dog for a walk just before I go to work. There, I have lunch with my colleagues, and afterwards I go to the gym. Once I'm back home, I take the dog for another walk and respond to patient emails, have dinner, then watch a news programme. I end the day by talking with family or friends on the phone, reviewing the latest medical publications on hepatology, and reading a book before going to bed.

When and how did you first find out you were living with hepatitis? What do you remember most about that moment?

In 2002, I was diagnosed with hepatitis C with liver cirrhosis. I was 33 years old. The doctor explained that I likely contracted it during surgery I had when I was 15, during which I received a blood transfusion. The doctor gave me little chance of a cure with treatment and told me I could live 10 to 15 more years. The diagnosis left me without hope, but thanks to the support of my family and friends, I quickly overcame the depression I had fallen into. I spoke to my virus, and told it that I would fight it until the last second of my life.

I dedicated myself to learning about the disease and everything related to treatment and liver research. I made changes to my lifestyle. The goal was to prepare myself as best as possible for my eventual treatment with pegylated interferon plus ribavirin, three years after my diagnosis.



If you could go back in time and give yourself advice at that moment, what would you say?

I think I would tell me to trust in myself. Also, that I'm not alone but have the support of family, friends, and many people who are also fighting the disease.

What's one thing you wish more people would understand about hepatitis?

I want people to know that hepatitis simply means inflammation of the liver and that there are many different causes that can lead to hepatitis. I also want them to recognise the importance of prevention for liver health, and leading a healthy lifestyle.

What's one thing that brings you joy, no matter what's going on in your life?

No matter how difficult the moment is, the simple things in life bring me peace and joy. Whether it's seeing someone smile, a bird singing, my dog playing with me, a delicious cup of coffee or meal, joking with my friends, or seeing my family happy.

Has hepatitis ever led you to discover something unexpected – about yourself, your strength, or even a new passion?

Illness showed me the value of enjoying these simple things in life. I also rediscovered my passion for medicine and confirmed my strong character.

Who has been your biggest supporter in your journey?

My family and friends have supported me at all times.

How do you think attitudes towards hepatitis are changing in your community – if at all?

Attitudes have not changed due to a lack of information. Society still maintains prejudices about hepatitis. Health authorities do not conduct ongoing information and prevention campaigns for liver disease either.

What's something you're looking forward to in the next year?

Next year, I want to strengthen teamwork with NGOs in Latin America and North America. I want to build synergy with liver cancer and diabetes groups. And I will seek to influence public policies of health authorities, so they can implement prevention campaigns and timely treatment for viral hepatitis.

What's one thing you'd like to say to others living with hepatitis?

They are not alone. And there is always something they can do to improve their liver health and have a better quality of life, so there is always hope.

This interview has been taken from the April-June 2025 issue of Hep Voice. Read all four 2025 issues here.







A MESSAGE FROM WHA CEO CARY JAMES



In 2025, WHA and its members have worked to ensure that the experiences of people living with hepatitis are not only heard, but acted upon by people with the ability to change systems.

Looking back, it is clear that progress was driven by a combination of stronger evidence, deeper community leadership, and more coordinated global action.

While milestones in national elimination efforts around the world show what is possible, new data reminds us that significant challenges remain. Our community-led research has strengthened the evidence base for hepatitis elimination, highlighting persistent gaps in awareness, access, and stigma, while identifying practical solutions to address them.

We have continued to bring this perspective to global decision-making spaces, advocating for hepatitis to remain a priority and for greater integration across health agendas. These insights are helping to inform more effective and equitable policies and programmes, with particularly important steps made in the connection between hepatitis and liver cancer through the influence of the United Nations (UN).

At the same time, our members have driven progress on the ground—expanding access to testing and care, raising awareness, and reaching underserved communities. WHA's global campaigns, such as World Hepatitis Day and World Hepatitis Testing Week, have demonstrated the strength and reach of our network, mobilising coordinated action across countries and contexts. Their expertise, grounded in lived experience, enables WHA to connect community realities with policy and decision-making.

As we look ahead to 2026, our focus is clear. With just four years remaining until the 2030 goal, the priority now is to translate commitment into impact at scale, and accelerate progress towards a world free from hepatitis.



Cary James, Chief Executive Officer

SNAPSHOT 2025

IMPACT

86 new members from **25** new countries

20 new publications

24 in-person and virtual events

140% increase in social media reach

ORIGINAL RESEARCH CONTRIBUTIONS to hepatitis stigma and discrimination and hepatitis delta

INFLUENCED GLOBAL POLICY OUTCOMES on liver cancer and NCDs

World Hepatitis Day 28 July

World Hepatitis Testing Week

46.8 million impressions for World Hepatitis Day and World Hepatitis Testing Week campaigns



OUR STRATEGY

WHA's 2021-2025 strategy focuses on accelerating action towards the elimination of hepatitis by 2030. At its heart, the strategy strives to elevate the people and communities impacted by hepatitis as well as the organisations working to fight for the elimination of hepatitis. It holds governing bodies to account for their commitments and it works to mobilise much needed resources for elimination.

Our strategy embraces a person-centred approach and the evolving landscape of health systems caused by COVID-19 and the evolution towards universal health coverage (UHC).

It looks to drive action through better integration within health systems including programmes addressing HIV and primary care. It seeks to create new partnerships to position hepatitis elimination as an essential element of liver cancer prevention and as a routine element of maternal and child health programmes.

The strategy is bold and ambitious and will cement WHA as a leading organisation not only in the hepatitis space, but the wider global health landscape as well.

The four strategic objectives for the strategy are:



Mobilise resources for hepatitis elimination across global health priorities, national health systems, and UHC programmes.



Hold governing bodies to account to achieve the 2030 elimination goals.



Increase the impact of our members and civil society organisations by building capacity, facilitating innovation, strengthening networks, and increasing collaboration across the elimination ecosystem.



Amplify the voice and visibility of empowered people living with hepatitis and the affected communities to increase empathy and motivate action by decision-makers.

FOUR PILLARS FOR 2025

WHA's work in 2025 was structured around four interconnected pillars, each designed to tackle key barriers to elimination while centring equity, accountability, and the lived experience of affected communities. These pillars guide our strategy and define how we drive progress towards the 2030 elimination goals.





ADVOCACY AND ACCOUNTABILITY

We drive action on viral hepatitis elimination across national health systems and the global health agenda by:

- Advancing UHC and strengthening health systems
- Embedding hepatitis across maternal and child health, non-communicable diseases (NCDs), and vaccination priorities
- Advocating for people who inject drugs and other affected communities
- Holding international bodies and national governments accountable to the 2030 commitments
- Increasing funding and resources available for elimination

COMMUNITY EMPOWERMENT

We build the power and potential of communities to lead the response by:

- Increasing the skills and abilities of civil society to advocate for and implement elimination
- Supporting and motivating individuals living with or affected by hepatitis
- Leading an activist movement grounded in equity, social justice and human rights

ELIMINATION ECOSYSTEM STRENGTHENING

We strengthen the global hepatitis response by:

- Facilitating a robust civil society network to share knowledge, experience and accelerate change
- Creating synergies between stakeholders across the elimination ecosystem to generate innovation, collaboration, and joint working

PARADIGM-SHIFTING COMMUNICATIONS AND COMMUNITY-BASED RESEARCH

We change the way the world sees hepatitis and those it affects by:

- Increasing knowledge and awareness of viral hepatitis, its impact, and the need for its elimination
- Generating empathy and compassion to influence behaviour and decision-making
- Providing evidence-based research and pilot projects that drive innovation and accelerate elimination

World Hepatitis Day 28 July

Each year on 28 July, individuals, organisations, policy-makers and governments around the world mark World Hepatitis Day (WHD) using WHA's campaign materials, endorsed by WHO.



QA English 9
Language: English
Type: Poster

Statement Spanish 2
Language: Español
Type: Poster

Statement China 2
Language: 中國傳統的
Type: Poster

THE WHD 2025 CAMPAIGN

Messaging

In 2025, we used the theme of 'Let's Break It Down', highlighting myths around hepatitis and factual answers recorded by doctors, urging people to get tested.

Resources

WHA developed free physical and digital assets, including posters, event flyers, social media graphics, video content, template advocacy letters, PowerPoint slides, Zoom/Teams backgrounds, and a campaign toolkit.

Posters and social media graphics were provided in five languages as standard for local use – Arabic, Chinese, English, French and Spanish – but our website also featured a bespoke tool to translate versions of these resources into any language.



Website


All resources were hosted on the campaign website, worldhepatitisday.org, while our paid digital advertising campaign also used audience analysis to direct people to areas of the site relevant to their interests.

Commentary


To reach health sector specialists and community advocates, WHA co-authored four articles in influential outlets:

- Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines (The Lancet)
- Let's break it down: Combating hepatitis stigma and discrimination (The Lancet)
- Eliminating hepatitis is cancer prevention (Union for International Cancer Control (UICC))
- Time to Eliminate the World's Second Deadliest Virus (Action for Global Health)









Online events

WHA also organised three WHD virtual events featuring high-level speakers, each attended by hundreds of viewers:

- **Breaking down hepatitis A** – plus its advocacy briefing, 'Hepatitis A: let's break it down' summarising key context and calls to action.
  Supported by MSD.
- **Scaling up hepatitis B birth dose** – co-hosted by WHA, Gavi, the Vaccine Alliance and WHO, with featured speakers from the Ugandan and Rwandan Ministries of Health sharing overviews of their countries' progress.
- **The annual WHD Community Forum** – This year's topic was, "How have stigma and discrimination impacted your life, and how can we overcome it as individuals and as a community?"

CAMPAIGN REACH:

31 million
social media impressions

Over
1.7 million
views of the WHD campaign video

96,000
website views

Global support across sectors

– from health ministries, industries, civil society organisations, global health bodies, and the UN

Results from our post-event survey:

98% of participants strengthened their capacity to impact their community and reach new audiences

86% increased awareness of hepatitis testing among clients and the local community

70% increased awareness of hepatitis among health professionals and other key stakeholders



Read the full WHD 2025 report here.

worldhepatitisday.org

World Hepatitis Day 2025 was supported by AbbVie, Gilead and GSK.

LIVER CANCER AND NCDs

Liver cancer is the third most common cause of cancer deaths worldwide, with viral hepatitis its leading cause. Hepatitis elimination is cancer prevention – and in 2025, WHA helped move it closer to adoption by health systems everywhere.



Hepatitis B and C account for at least 76% of all liver cancer cases worldwide, yet awareness remains troublingly low, with research conducted by WHA finding that nearly half (42%) of people globally were unaware of the link.

Making our voice heard

In 2025, WHA focused on the absence of hepatitis testing, treatment and vaccination of hepatitis from most national cancer control strategies and NCD discussions. Without swift action, this disconnect between hepatitis and cancer control strategies will contribute to a projected doubling of liver cancer cases by 2040.

WHA rallied support, published advocacy resources and held events to raise the issue's profile, while attending meetings at the highest levels. We repeatedly emphasised the necessity of integrating hepatitis interventions into national cancer programmes and broader NCD strategies.

White paper

WHA wrote a white paper, **Beating cancer through hepatitis elimination: working together to reduce NCDs**, followed by a summary version for community groups to use in their advocacy work. This was launched at the 78th World Health Assembly during two events co-hosted by WHA. You can read about these at **worldhepatitisalliance.org/beating-cancer/**

Download the whitepaper at **worldhepatitisalliance.org/whitepaper**

The UN HLM NCDs

2025 also presented a key opportunity for hepatitis and cancer advocates.

The **fourth United Nations (UN) High-level Meeting (HLM) on the prevention and control of NCDs and the promotion of mental health and wellbeing** took place on 25 September 2025 – which resulted in a political declaration that reinforced countries' commitments to accelerating NCD prevention and control. WHA brought together a coalition of partners to push for the inclusion of hepatitis in the new declaration.

The UN HLM and Political Declaration on NCDs – how WHA and partners made history

2 May 2025

UN Multistakeholder meeting, WHA attends and called for the inclusion of hepatitis testing, treatment and vaccination as well as monitoring for liver cancer in the new political declaration.

June 2025

Zero draft of the political declaration released.

July 2025

WHA and partners pushed for our draft text to be included by engaging UN Member States throughout the political declaration negotiations.

23 September 2025

Ahead of the UN HLM, WHA convenes advocates and decisions-makers to a side meeting in New York, 'Reimagining approaches to beating NCDs and liver cancer'.

Supported by AstraZeneca

25 September 2025

The UN HLM is held, and WHA and partners' wording is included in the final draft of its political declaration.

December 2025

Success! The political declaration is adopted, making it the first UN endorsement of hepatitis testing and treatment as cancer prevention.

To support members, partners, and advocates engage in the process, WHA published **a briefing in preparation for the UN HLM on NCDs** and following its adoption, **a briefing on how we can turn the commitments of the political declaration into action.**

Learn more about WHA's work around the UN HLM and access the latest briefing at worldhepatitisalliance.org/unhlm

ELIMINATING VERTICAL TRANSMISSION

SAFEStart+

SAFEStart+ is a new four-year project led by PATH, together with WHA and ICWEA, made possible through partnership and funding from Unitaid.

Launched in July 2025, the project aims to accelerate demand and adoption of evidence-based approaches and integrated delivery strategies to eliminate vertical transmission (EVT) of HIV, syphilis, hepatitis B, and Chagas disease.

By improving health system efficiencies, and introducing new diagnostic, treatment, and prevention tools, SAFEStart+ will save the lives of thousands of mothers and babies. Furthermore, it is designed to support communities to develop their own people-centred services that meet local needs and can be scaled to reach even more underserved populations.

In late 2025, SAFEStart+ began its process for recruiting a Global Community Advisory Board, and individual Country Community Advisory Boards, centring the expertise of people with lived experience and local knowledge.

SAFEStart+ is working to:

- Scale up integrated EVT programs in four core engagement countries: Malawi, Nigeria, Paraguay, and Uganda
- Address specific barriers to EVT scale-up and validation in five focused-activity countries: Brazil, Democratic Republic of the Congo (DRC), Senegal, South Africa, and Vietnam
- Actively disseminate innovations, successes, and lessons learnt to further increase adoption and scale-up of evidence-based EVT approaches in ten peer-learning countries: Cambodia, Cote d'Ivoire, El Salvador, The Gambia, Ghana, Kenya, Mozambique, Philippines, Tanzania, and Zimbabwe

Learn more at worldhepatitisalliance.org/safestart





NOhep Mums

As part of World Hepatitis Testing Week 2025, WHA launched the **NOhep Mums In-Country Programme: Accelerating Access to Antenatal Testing for Hepatitis B**. This programme focused on the virus' most common transmission from mother to child, and enrolled five WHA members across five countries to identify and support actions that would have the greatest impact driving change around hepatitis B in their local settings.

Thank you to **National Liver Foundation of Bangladesh, YOUTHAID Liberia**, Nigeria's **Hope Life Support and Empowerment Initiative**, Sierra Leone's **Supporting Entrepreneurship and Economic Development**, and **Vision Outreach Zambia** for all their work! Learn more about the programme and these five WHA members here:

Discover the vital work of the NOhep Mum's programme at worldhepatitisalliance.org/nohepmums

Supported by Abbott

Preventing Future Infections

Hepatitis B is a major concern in Senegal, West Africa, where almost 1 in 5 people live with the virus. Due to unequal distribution of services, remote and deprived communities are most likely to be affected, but are also the least likely to have access to healthcare.

Preventing Future Infections: Empowering Communities to Break the Transmission of Hepatitis B from Mother-to-Child was a project undertaken in 2025 by WHA member SAAFARA Hépatites Sénégal, with funding from WHA and Kedrion, to tackle this problem for pregnant women in the town of Guédiawaye, Dakar.

OUTCOMES

For mothers

Healthcare providers have reported an increase in confidence and hepatitis B testing among pregnant women.

At the community level

Outreach sessions about hepatitis B, including 52 talks, radio broadcasts, and training for journalists, reached more than 1,900 people.

For health systems

SAAFARA training sessions have improved the capacity of 50 frontline healthcare providers to apply screening, birth dose vaccination and treatment protocols.

Politically

SAAFARA's advocacy secured support from local authorities, national stakeholders, and key opinion leaders. Together, this has relocated hepatitis B more firmly within maternal and child health outcomes and helped normalise conversations of the virus, reducing local stigma and encouraging active promotion of testing.



Watch SAAFARA's impactful project video here



Read the project's full report at worldhepatitisalliance.org/future-infections

This project was funded by Kedrion SPA – unrestricted grant.

World Hepatitis Testing Week 2025

World Hepatitis Testing Week 2025 (WHTW), WHA's international campaign to increase testing and combat the global rise of hepatitis, took place from 17 to 22 November – with individuals, organisations, and partners around the world raising awareness online and in their communities.




Resources

WHA developed a distinct visual and messaging identity for WHTW, a suite of customisable resources in multiple languages – from printable posters to social media assets – and video content for supporters around the world to use.

The campaign

Quiz: Should I get tested for hepatitis?


Central to this year's campaign was an online quiz, to help people understand whether they should consider getting tested for hepatitis, and why, by answering three simple questions.



Map: A world united for testing week

Another key tool launched this year was a global map of support for WHTW. Organisations working in hepatitis could add their details to help people find them in different regions, with 502 groups joining by the end of the week.





Website

All WHTW campaign elements were hosted on the dedicated website heptestweek.org, providing a central hub. Our paid digital advertising also used audience analysis to direct people to areas of the site relevant to their interests.

Online events

A series of community workshops and webinars hosted by WHA made WHTW an essential source of new information and best practices around hepatitis:

- **Community workshops in English, French and Spanish** – led by Daniela Rojas Castro, these sessions focused on the effective implementation of community-based hepatitis testing.
- **Scaling up hepatitis delta testing: breaking barriers, seizing opportunities** – this session highlighted urgent challenges in screening and access to care, promising developments in the treatment pipeline, and insights from WHO on their newly released hepatitis delta guidelines.

Supported by Bluejay Therapeutics.

- **Innovative approaches to hepatitis testing** – exploring strategies to expand testing in non-traditional settings to reach underserved populations, and integrating hepatitis testing into cancer and mental health programmes.
- **Scaling up hepatitis B within triple elimination programmes** – highlighting how simplified testing for pregnant women and families enables timely prevention and creates pathways to eliminate vertical transmission of HIV, syphilis, and hepatitis B. During the webinar, WHA launched a community briefing outlining clear calls to action for advocates.

Supported by Abbott.

REACH

Over **12.7m** social media impressions

25,000 website views

Over **1.3m** views of WHTW campaign videos

502 organisations pledging support on the WHTW map



Every year, this week renews my hope that with awareness, compassion and simple testing, we can prevent unnecessary suffering and move closer to a future free from hepatitis."

– WHTW survey feedback

Results from our post-event survey:

94% of participants said WHTW increased their capacity to reach new people.

89% said it increased their organisation's capacity to impact their community

83% said it increased awareness of hepatitis testing and other hepatitis issues among clients and the local community

Read the full World Hepatitis Testing Week 2025 Report here:
heptestweek.org

World Hepatitis Testing Week was made possible with support by Gilead Sciences, Abbott, AbbVie, GSK, Roche, Bluejay Therapeutics and InTech.

PROJECT PROFILE

Community Impact Programme

The Community Impact Programme (CIP) is a WHA initiative designed to equip advocates and community leaders with the knowledge, skills, and tools to drive action towards the elimination of hepatitis by 2030. Workshops, mentoring, and peer-to-peer learning help participants gain practical experience in advocacy, policy engagement, storytelling, and partnership-building, and go on to lead impactful initiatives in their own communities.

The Accelerator Programme

The Accelerator Programme is CIP's participatory training scheme. Over 12 weeks, each participant develops real advocacy projects rooted in their daily work and national and organisational contexts.

Running between April and July, the first edition of 2025 was tailored for Spanish-speaking advocates and drew participants from across Latin America and Spain. The course was delivered through virtual sessions, culminating in a two-day workshop in Bogotá, Colombia, where participants also attended the Harm Reduction International Conference 2025.

The second Accelerator Programme of 2025 took place between September and December, bringing together a diverse group of 18 international attendees from a wide range of experiences, and expertise. Participants included grassroots advocates and organisational leaders, all united by a shared commitment to hepatitis elimination.

The Accelerator Programme has proven to be a highly valuable learning experience, equipping participants with diverse skills and practical knowledge to strengthen their advocacy efforts. It has also been strongly endorsed, with 100% of participants stating they would definitely recommend the programme to others.

Programme supported by the John C Martin Foundation

CASE STUDY


Jose Angel is a sexual health mediator at Apoyo Positivo, an NGO based in Spain defending the rights of people affected by HIV and their integration into society. In April 2025, Jose joined the third group of the Accelerator Programme, saying it provided "a unique opportunity to strengthen my role as an agent of change."

As a part of the programme, Jose was supported to attend the Harm Reduction International Conference (HRIC) 2025 in Bogotá, Colombia. "Attending had a strong impact on my work. It exposed me to realities of harm reduction, displacement, and quality of life in regions I was less familiar with. The panels, presentations, and posters broadened my perspective and strengthened my commitment to community-led advocacy."

Attending HRIC also led to networking opportunities, where Jose forged new partnerships across borders, such as with Apothicom France. "We explored the possibility of sharing harm reduction tools, training materials, and community-based resources related to chemsex and STIs. Given the proximity and shared migration routes between France and Spain, this is especially relevant when addressing the needs of migrant communities."

Since completing the programme, Jose has implemented lessons learnt: "I have applied the skills and tools from CIP by combining them with my community-based experience and adapting them to the real needs of our organisation. The programme helped me structure advocacy work with a clearer strategy, teamwork approach, and social support focus. I would absolutely recommend CIP."

Read full case studies and download our Accelerator Programme Impact Reports at **worldhepatitisalliance.org/cip-accelerator/**



E-learning

CIP is also open to all as a free e-learning platform. Visitors can explore modules on different topics around hepatitis advocacy specifically, and health advocacy more broadly.

In 2025, we published four exciting new modules:

Writing an abstract – featuring a special video seminar of guidance by Rob Brierley, Editor-in-Chief of The Lancet Gastroenterology & Hepatology.

Presentation skills – to overcome nerves and build confidence when explaining ideas and showing them to an audience.

Storytelling – to learn how simple techniques as old as humankind, and the power of people's voices, can cut through the noise to reach audiences.

Mental health and hepatitis – to build knowledge and become an effective advocate for mental health support in hepatitis services.

To learn more, visit **worldhepatitisalliance.org/cip-e-learning/**

NOHEP MEDICAL VISIONARIES

The NOhep Medical Visionaries Programme is a practical, peer-led movement by WHA equipping medical professionals with the knowledge and tools they need to lead the fight against viral hepatitis, and empower them to advocate for its elimination.



NOhep



In 2025, WHA provided new resources on mental health to NOhep's base, an updated identity, and hosted NOhep events online and at influential conferences on liver health.

Mental health

Hepatitis and mental health have an important relationship. Studies have found that people living with severe mental illness have an increased prevalence of hepatitis B and hepatitis C in comparison to the general population, while people living with viral hepatitis often experience mental health challenges around their diagnosis and social stigma and discrimination.

Integrating mental health and hepatitis care has become increasingly essential, with screening in mental healthcare settings an important part of a comprehensive hepatitis elimination response. Understanding the mental health challenges faced by people living with viral hepatitis, and providing access to support, became a key focus of NOhep's work in 2025.

To support this, two important NOhep guides – the **Mental Health and Viral Hepatitis Guide**, and **Viral Hepatitis Testing and Treatment Guide** – were published to ensure up-to-date knowledge and best practices among healthcare professionals.

These were introduced alongside **Integrating Mental Health into Hepatitis Care**, a profile of Dr Renee Logan and Dr Jordan Feld, exploring how they used collaboration, partnerships and integration to contribute to viral hepatitis elimination goals and improve patient outcomes. And in October, NOhep and the **European Psychiatric Association** came together to present **Bridging the Gap: Integrating Mental Health and Hepatitis Care**, a virtual event to discuss strategies organisations can use in their own work.

Learn more at **nohep.org/mental-health/**



NOhep Medical Visionaries Forums

A key part of NOhep's work is to capture the attention of healthcare practitioners and decision-makers internationally through forward-thinking forums. In 2025, **NOhep Medical Visionaries Forums** took place at the following conferences – click the links to read recaps:

- **Indian Hepatitis Summit 2025**, Chennai, India, under the theme *Innovations in Technologies: The Role of Technology in Hepatitis Elimination*
- **EASL 2025**, Amsterdam, Netherlands, under the theme *Accelerate action now: Strategies to scale-up hepatitis elimination*
- **ISAM Congress 2025**, Washington DC, USA, under the theme *Addressing Addiction, Mental Health and Hepatitis to Improve Outcomes*
- **INHSU 2025**, Cape Town, South Africa, under the theme *Integrating Mental Health, Harm Reduction and Hepatitis Care to Improve Outcomes*
- **The Liver Meeting (AASLD) 2025**, Washington DC, USA, under the theme *Same Virus, Different Rules?*

Updated identity, guide and principles

As the movement approached its tenth year, NOhep received a refreshed look with a new green and simplified logo. The NOhep Medical Visionaries Guide and its organising principles were also updated to better reflect what it means to be a NOhep Medical Visionary in 2025:

Educate Peers

Be a Vocal Ambassador

Gather Allies

Advocate to Governments


Learn more at **nohep.org/medical-visionaries/**

Supported by AbbVie


HEPATITIS DELTA GLOBAL LANDSCAPE SURVEY REPORT

Hepatitis delta, also known as hepatitis D, is a severe form of viral hepatitis that is often overlooked. Affecting only those already living with chronic hepatitis B, delta is responsible for around 20% of liver disease and liver cancer cases among people with hepatitis B and causes far faster progression to severe illness.

HOW FAMILIAR ARE YOU WITH HEPATITIS DELTA?




Only 20% of respondents said hepatitis delta treatment is both available and accessible in their country




1 in 3

respondents did not feel sufficiently informed to identify barriers to hepatitis delta treatment







HEALTHCARE PROFESSIONALS EXPRESSED A CLEAR INTEREST IN FURTHER EDUCATION ON THE TOPIC



TRAINING ON HEPATITIS DELTA TESTING

64%



TREATMENT AND CARE

60%



THERAPEUTIC INNOVATION

55%

Globally, an estimated 12 million people are affected, but awareness is dangerously low, data is limited, and access to screening and treatment is often non-existent, even in regions where the disease is endemic.

WHA's Hepatitis Delta Global Landscape Survey was designed to get to the heart of this problem by providing much needed data. A total of 583 individuals participated in the survey, representing healthcare professionals (45.2%), community-based organisations (29.5%), policy-makers (4.7%), and others, including people living with hepatitis, students, and patient advocates.

The findings of this survey, published as the "Hepatitis Delta Global Landscape Survey Report" in 2025, revealed shocking truths and offered clear calls to action to governments, health systems and global health actors.

Download the full report at worldhepatitisalliance.org/hepatitis-d-survey

Financial support for this project provided by Vir Biotechnology Inc

THE HEPATITIS STIGMA SURVEY

Stigma can be one of the most damaging aspects of life with viral hepatitis. It can impact mental health, fracture relationships, limit career opportunities, and even deter people from accessing the healthcare they need. It's driven by persistent myths, misinformation, and misunderstandings about how hepatitis is transmitted. It continues to be a major barrier to global elimination.

To tackle stigma effectively, we need to understand what it looks and feels like for people living with hepatitis B and C. While global tools are available to measure stigma for other conditions, there has not been a tool for viral hepatitis. That's why in 2024, in partnership with the European Centre for Disease Prevention and Control (ECDC), WHA piloted the Hepatitis Stigma Survey.



When I was first diagnosed with hepatitis B, I, like many others, didn't know it can't be transmitted through casual contact. I felt a sense of shame and I faced a lot of pressure. The diagnosis really affected my confidence and my mental health. I thought hepatitis B was a death sentence."

Danjuma Adda

Developed with input from global stakeholders and people with lived experience, the survey was piloted in nine countries: Bulgaria, Croatia, Cyprus, Denmark, Germany, Portugal, Spain, Romania and the UK. The results, which were published in a report titled **"Measuring stigma and discrimination related to hepatitis B and C"** in 2025, revealed just how deeply stigma can affect people's everyday lives. WHA will look to expand this important survey globally in 2026.

Download the full report at worldhepatitisalliance.org/stigma

BRIEFING Measuring stigma and discrimination related to hepatitis B and C

World Hepatitis Alliance

The World Hepatitis Alliance (WHA), in collaboration with the European Centre for Disease Prevention and Control (ECDC), conducted a survey to explore stigma and discrimination experienced by people living with hepatitis. The survey was piloted in Bulgaria, Croatia, Cyprus, Denmark, Germany, Portugal, Romania, Spain, and the UK.

48%
of those affected by hepatitis C said that they had/have **poor self-esteem** because they are/were living with hepatitis.

1 in 6
of those living with hepatitis C said that **family members had made discriminatory remarks** about them.

1 in 10
of those living with hepatitis B and hepatitis C have been **threatened, verbally abused or physically harmed** by a sexual partner.

57% of those affected by hepatitis C
46% of those living with hepatitis B
found it **difficult to tell people** they are/were living with hepatitis.

70% of those affected by hepatitis C
44% of those living with hepatitis B
have/had **concerns that they could pass it on** to others.

7%
of both those living with hepatitis B and those living with hepatitis C have been **denied employment or fired** due to their hepatitis.

34% of those living with hepatitis C
25% of those living with hepatitis B
have been **worried that they would be treated differently from other patients** by healthcare staff.

24% of those living with hepatitis C
15% of those living with hepatitis B
reported **avoiding going to healthcare services** when they needed to because they expected to be treated differently.

Healthcare settings must do more to provide a stigma-free service for people living with hepatitis.

More efforts are needed to address mental health issues to improve the quality of life of those living with hepatitis.

More support must be given to people living with hepatitis who face discrimination in employment and other social settings.

Read the full report "Measuring stigma and discrimination related to hepatitis B and C" on the WHA website worldhepatitisalliance.org/stigma

COMMUNICATIONS

Beyond our main campaigns, like World Hepatitis Day and World Hepatitis Testing Week, WHA works towards its organisational objectives each year through the development of paradigm-shifting communications across print and digital channels, for both shorter- and longer-term purposes.

This involves developing effective resources for specific audiences, working efficiently to keep results on time and to budget, and testing and iterating improvements to working methods and outputs.

Here are just some of WHA's communications successes in 2025:

Social media

WHA saw a major increase in engagement across its social media accounts, with over 2,300 new followers and a more than 140% increase in reach. On LinkedIn alone, we achieved 2.2 million impressions in 2025.

Awareness raising campaigns

Our social media strategy involved a refreshed approach to **awareness day communications** linked and promoted relevant awareness days to work WHA is doing around our organisational priorities and CIP modules. These milestones included:

- **International Day for Maternal Health and Rights**
- **International Day of Education**
- **International Day of the World's Indigenous Peoples**
- **International Men's Health Week**
- **International Women's Day**
- **International Youth Day**
- **Liver Cancer Awareness Month**
- **UHC Day**
- **World AIDS Day**
- **World Breastfeeding Week**
- **World Cancer Day**
- **World Health Day**
- **World Immunisation Week**
- **World Liver Day**
- **World Mental Health Day**
- **World TB Day**
- **World Water Day**

Resources

We applied this same approach to the schedules of key **briefing notes and toolkits**, developing and publishing them to coincide with relevant awareness days.

By using infographic-inspired layouts, we have expanded their potential for use as resources. All of these are now easier to find on our website, too, and regularly shared in our weekly communications through our social media channels and email newsletter.

Hep Voice

WHA's flagship digital magazine **Hep Voice** continued to be published each quarter in 2025, reaching 13,000 readers with news and actions to take from the global hepatitis landscape, important dates for diaries, updates on WHA's work and campaigns, and interviews with people with lived experience of hepatitis.

Based on feedback from 2024, we experimented with longer format profiles of key issues, individuals and organisations from the international hepatitis community. This was well-received by readers and interviewees alike, such as **Waklisa Development Association** in Ethiopia, who were featured in our March 2025 issue:

"I read the magazine again and again. I am so glad our effort from the hard-to-reach nomadic community reached the entire world. This recognition will be used as fuel to achieve better results in the elimination of hepatitis. I and the entire Waklisa Development Association team are very thankful for this chance."

View all our 2025 issues of Hep Voice here.



NEW MEMBERS 2025

A very warm welcome to all our new members! WHA expanded by **86 new members** in 2025, including organisations from **25 new countries** (in bold below), bringing total membership to **451 members in 129 countries**.

ORGANISATION	COUNTRY
Acção de Solidariedade e Saúde Comunitária (ASSC)	Angola
People PLUS	Belarus
Human Rights and Forest Brain Africa (Hurifba)	Cameroon
For The China Liver Health	China
Magdalena OPS	Czech Republic
PLAPERTS-E	Ecuador
Gabon SOS Hepatites	Gabon
Association des Jeunes Contre la Discrimination et la Stigmatisation (AJCDS)	Haiti
Refuge des femmes d'Haïti (Ref-Haiti)	Haiti
Fundación Hondureña para la Salud Hepática (FUNHEPA)	Honduras
Háttér Society	Hungary
National Empowerment Network of People Living with HIV/AIDS in Kenya (NEPHAK)	Kenya
Association of Health Programs Partner Network	Kyrgyz Republic
Community Health and Inclusion Association (CHIAs)	Laos
Associação Moçambicana para Saúde e Ambiente	Mozambique
Community Mental Health and Development Initiative	Nigeria
Movimiento de Mujeres Positivas	Panama
OZ Odyseus	Slovakia
Dom Svetla Slovensko	Slovakia
Sudan Family Planning Association	Sudan
Republican Public Organization Afif	Tajikistan
Convictus	Ukraine
Vision Outreach Zambia	Zambia
AIVL – Australian Injecting & Illicit Drug Users League Ltd.	Australia
Lhak-Sam (BNP+)	Bhutan
Instituto para el Desarrolo Humano	Bolivia
Men for Health and Gender Justice Organisation	Botswana
Khmer HIV/AIDS NGO Alliance (KHANA)	Cambodia
Yiyou Charity Liver Center	China
Kenya AIDS NGOs Consortium	Kenya
LVCT Health	Kenya
AINGA/AIDES	Madagascar
Malaysia Society for Harm Reduction	Malaysia
Union for Equity and Health	Moldova
AIDS and Rights Alliance for Southern Africa (ARASA)	Namibia
ONG DIKO	Niger
Pre-eminent Empowerment and Development Foundation	Nigeria
Drug Free and Preventive Healthcare Organisation	Nigeria
Nai Zindagi Trust	Pakistan
Fundación Vencer	Paraguay
Šanca pre pečeň OZ	Slovakia
Support the Needy Initiative	South Sudan
APCOM Foundation	Thailand
Dreamlopments Foundation	Thailand
Alliance for Public Health	Ukraine
Youth Movement for HIV/TB/SRHR Advocacy in Zambia	Zambia
ONG Nouvelle Vision	Benin
Asociacion Colombiana de Enfermos Hepaticos y Renales	Colombia
Association Congolaise pour l'Assistance Sociale (ACAS)	Republic of Congo
ACCESS Health International	Egypt
Angels in the Field	India
Society for Promotion of Youth & Masses (SPYM)	India
Global Health Association of Kenya	Kenya
Association Justice et Miséricorde (AJEM)	Lebanon
SOS Hepatite Niger	Niger
Doxa Health Foundation	Nigeria
Supreme Care Health Foundation	Nigeria
Health Care and Development Association	South Sudan
Afya Plus	Tanzania

ORGANISATION	COUNTRY
Tanzania Health Alliance (THA)	Tanzania
V-Life Savers Foundation	The Gambia
Alpha Action for Social and Economic Development (AASED)	Uganda
United for Children's Inter-Development Action Uganda (UNCIDA)	Uganda
Hep B Companion	United Kingdom
We Give All to Combat Hepatitis and Liver Cancer	United Kingdom
Association Burundaise pour un Monde de Paix sans Drogues (ABMPD)	Burundi
Burundi Association of People Who Use Drugs (BAPUD)	Burundi
Association Yemini Santé	Republic of Congo
Mission d'Evangélisation aux Groupes Marginalisés (MGM)	Democratic Republic of the Congo
Yayasan Gerakan Mandiri Pita Merah (GEMPITA)	Indonesia
Hepatitis Advocates Kenya	Kenya
YOUTHAID-LIBERIA (YAL)	Liberia
Sali Hoe Foundation	Nigeria
Equal health and Rights Access Advocacy Initiative (EHRAAI)	Nigeria
Education as a Vaccine	Nigeria
Integral Global	Pakistan
HIV/AIDS Support Organisation of Seychelles (HASO)	Seychelles
Supporting Entrepreneurship and Economic Development (SEED)	Sierra Leone
Sediba Hope Medical Center	South Africa
Asia Lanka Social Development Co-operation (ALSDC)	Sri Lanka
Community Health And Development Foundation (CHADF)	Tanzania
Agago Action for Good Health from Uganda	Uganda
Bewell Childcare Initiative (BCI)	Uganda
Public Organization "BCD"	Ukraine
Texas Liver Care Foundation	USA
ISHONCH VA HAYOT	Uzbekistan





GOVERNANCE AND FINANCIAL OVERVIEW

WHA BOARD AND LEADERSHIP

The World Hepatitis Alliance Board is made up of a majority of board members who have personal experience of living with hepatitis B or hepatitis C. This includes:

- The president and president-elect or immediate past-president, who are appointed by the board.
- A board member from each of the six WHO regions, who are elected by the World Hepatitis Alliance members in their region.
- Alongside this there are also a limited number of board members who have been appointed due to their specific skills, knowledge or expertise.
- Board members are unpaid and their primary role is to provide governance and strategic direction to the organisation and in doing so make sure that we always remain an organisation for people living with viral hepatitis.
- The board is supported by a staff team who are primarily based in London who undertake the day-to-day operational delivery of the organisation's strategy.

CHANGES TO BOARD IN 2025

At the end of 2025, WHA's board cycles took place, including regional board elections and a changeover to the presidential roles.

Dee Lee, Director of Inno Asia since 2023 and former Director of Inno Community Development Organisation, formally assumed the position of WHA President from 1 January 2026. Rachel Halford will stay on throughout 2026 as Past President to ensure a smooth transition and bolster WHA's position on the global stage.

Regional elections were held at the end of 2025 for the EMRO and EURO board member positions. Having served the maximum amount of consecutive terms, Professor Gamal Shiha stepped down as EMRO board member. Dr Riham Soliman, a consultant hepatologist and active member of the Association of Liver Patient Care (ALPC) from Egypt, was elected to represent the EMRO region for the next two years. Luis Mendao, Director-General of GAT-Treatment Activists Group in Portugal, was re-elected to represent the EURO region.

Additionally, three new skills-based board members were brought onto the board to strengthen the depth and range of knowledge it holds. These included; Dr Nick Walsh, a physician and public health specialist from Australia, Sonali Johnson, Head of Knowledge, Advocacy and Policy at the UICC in Switzerland and Caroline Thomas, Founder of Peduli Hati Bangsa Foundation in Indonesia.



Rachel Halford
President, UK




Dee Lee
President-elect, China



Shaibu Issa – AFRO Board Member, Tanzania




Dr Gamal Shiha – EMRO Board Member, Egypt



Luis Mendao – EURO Board Member, Portugal



Ebuka Emebinah
Treasurer, UK



Antonio Onate – PAHO Board Member, Mexico



Reazul Islam – SEARO Board Member, Bangladesh



Thomas Tu – WPRO Board Member, Australia



Dr Nick Walsh – Skills-based board member, Australia




Caroline Thomas
Skills-based board member, Indonesia




Sonali Johnson – Skills-based board member, Switzerland

INCOME AND EXPENDITURE STATEMENT

INCOME BREAKDOWN (2025)



EXPENDITURE BREAKDOWN (2025)



INCOME STATEMENT

For the year ended 31 December 2025

	2025				2024
	Restricted income and expenses	Unrestricted income and expenses	2025 Total		2024 Total
INCOME					
Programmes	£509,492	£36,041	£545,533		£1,211,770
Core	£0	£85,805	£85,805		£185,934
Interest Income	£0	£11,676	£11,676		£20,628
Other Revenue	£0	£8,920	£8,920		£4,093
TOTAL INCOME	**£509,492**	**£142,441**	**£651,933**		**£1,422,424**
EXPENDITURE					
Staff	£613	£688,507	£689,120		£617,778
Equipment, office and overheads	£19,037	£86,129	£105,166		£100,253
Travel and representation	£84,037	£37,715	£121,751		£363,052
Communications	£56,275	£29,073	£85,348		£107,390
Consulting and outsourced support	£41,126	£15,993	£57,119		£137,933
Voluntary contribution	£30,833	£13,348	£44,181		£22,222
Project management and overhead recharges	£474,631	-£474,631	£0		£0
TOTAL EXPENDITURE	**£706,552**	**£396,134**	**£1,102,686**		**£1,348,629**
FOREIGN EXCHANGE GAIN / LOSS	**-£11,017**	**-£16,460**	**-£27,478**		**-£11,031**
OPERATING PROFIT	**-£208,078**	**-£270,153**	**-£478,231**		**£62,764**
Balance sheet allocations	£207,672	£0	£207,672		£52,559
Transfers between funds	£406	-£406	£0		£0
RESULT FOR THE YEAR	**£0**	**-£270,559**	**-£270,559**		**£115,324**
RETAINED EARNINGS AT 1 JAN	**£0**	**£832,299**	**£832,299**		**£716,975**
RETAINED EARNINGS AT 31 DEC	**£0**	**£561,739**	**£561,739**		**£832,299**

BALANCE SHEET

At 31 December 2025

ASSETS	31 DEC 2025	31 DEC 2024
CURRENT ASSETS		
Cash and cash equivalents	£429,201	£1,005,862
Prepayments and accrued income	£169,088	£20,839
Other debtors	£59,461	£81,838
FIXED ASSETS		
Tangible fixed assets	£278	£664
TOTAL ASSETS	**£658,028**	**£1,109,203**
LIABILITIES		
CURRENT LIABILITIES		
Accounts payable	£33,677	£11,789
Accruals and deferred income	£43,304	£46,970
Other liabilities	£19,307	£15,296
NON-CURRENT LIABILITIES		
Restricted funds	0	£202,850
TOTAL LIABILITIES	**£96,289**	**£276,905**
NET ASSETS	**£561,739**	**£832,299**
EQUITY		
Current Year Earnings	-£270,559	£115,324
Unrestricted Net Assets	£832,299	£716,975
TOTAL EQUITY	**£561,739**	**£832,299**

ACKNOWLEDGEMENTS AND PARTNER RECOGNITION

The World Hepatitis Alliance is proud to work alongside a wide range of charitable foundations, private companies, and individual supporters who share our vision of a world free from viral hepatitis. Our partners play a vital role in advancing our mission; their support and commitment underline the importance of empowering civil society, amplifying the voices of people living with hepatitis, and driving progress toward elimination.

Our supporters contribute in diverse ways – from strategic, multi-year partnerships, over project-specific grants, to annual contributions through our WHA Supporter Circle, and campaign-specific donations of tests or resources.

In 2025, we expanded the areas of engagement in our work towards a whole health system approach through actions like the advocacy surrounding the World Health Assembly and UN HLM on NCD where we were a part of securing the acknowledgement of hepatitis prevention, diagnosis, treatment, vaccination, and monitoring as cancer prevention. This opened new sources of funding both for hepatitis elimination as a whole and for WHA in particular.

This variety of support is essential for both WHA and our members, enabling us to deliver impactful programmes, global campaigns, and high-level advocacy that foster long-term change. In return, our partners benefit from alignment with a globally respected organisation and a meaningful opportunity to demonstrate leadership in public health and patient-centred action. Our partners gain access to WHA's global reach, technical expertise, and trusted relationships within the hepatitis community – ensuring that funded projects, events, and campaigns deliver measurable, lasting impact.

We are committed to fostering mutually beneficial, long-term partnerships grounded in shared values. We extend our heartfelt thanks to all our donors and partners for their invaluable support in 2025. Without their commitment and collaboration, none of our work would be possible!



OUR SUPPORTERS

Abbott

AbbVie

Aligos Therapeutics

AstraZeneca

Bluejay Therapeutics

Cepheid

Gilead Sciences

GSK

InTec

Kedrion Biopharma

MSD

Roche

The John C Martin Foundation

Vir Biotechnology

Virion Therapeutics

Support for SAFEStart+ was provided by PATH on behalf of Unitaid



WHA SUPPORTER CIRCLE

In 2025, we continued to expand the WHA Supporter Circle – the annual partner commitment which we launched in 2024.

The Supporter Circle officially aligns partners with WHA, a globally recognised, highly respected, patient-led organisation. It also brings partners closer to WHA's membership network and helps deliver on their objectives through the reach, insight, resources, and tools that WHA is uniquely placed to provide.

In addition to making an annual financial contribution at one of four levels, members of the Supporter Circle commit to a shared principle:

To do all they reasonably can to centre the voices of people living with hepatitis in decisions that affect them, and to recognise the critical role these individuals and their organisations play in achieving hepatitis elimination.

This commitment reflects the core values of WHA and our members. It underscores the importance of building a strong, inclusive, and collaborative community to accelerate progress. Together, we can achieve a world without viral hepatitis!



World Hepatitis Alliance

Email
contact@worldhepatitisalliance.org

Main phone number
+44 (0) 20 7031 6904

Swiss phone number
+41 (0) 22 518 0616

UK office
Unit 2, 27 Corsham Street, London
N1 6DR United Kingdom

Address
Rue de Rive 4, 1204 Genève
Switzerland



World Hepatitis Alliance

2025